STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #866 by analyst upside · 2026-06-27
CRMD
CorMedix Inc.
Healthcare · Market Cap $616M · P/E 3.6x
ANALYST PRICE TARGET
+93.6%
implied upside to consensus target
Current Price $7.85
Consensus Target $15.2
Bull Target $19.0
Bear Target $13.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
0
Sell
0
52-Week Low $6.13
52-Week High $14.96
YTD Return -35.4%
FUNDAMENTALS
Market Cap $616M
P/E Ratio (TTM) 3.6x
Forward P/E 22.4x
EPS (TTM) $2.21
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $400M
Profit Margin 45.2%
52-WEEK RANGE
52-Week Low $6.13
52-Week High $14.96
Current Price $7.85
Bear Target $13.0
Bull Target $19.0
● Now $7.85 ● Target $15.2
TRADING DATA
Avg Volume 1.3M
YTD Return -35.4%
Analyst Count 5
Consensus Buy
Upside to Target +93.6%
Last Updated 2026-06-27

ANALYST SUMMARY

CorMedix Inc. (CRMD) is currently trading at $7.85 with a Wall Street consensus price target of $15.2, implying potential upside of 93.6% over the next 12 months. 5 analysts currently cover CRMD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $19.0, while the most cautious has a target of $13.0.

CRMD operates in the Healthcare sector with a market capitalisation of $616M. The stock is down 35.4% year-to-date and is currently trading near the lower end of its 52-week range of $6.13 – $14.96.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CRMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital — Reiterated
Outperform → Outperform 2026-04-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-04-28 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-04-28 29% win rate (7 calls)
Needham — Reiterated
Buy → Buy 2026-04-27 20% win rate (5 calls)
D. Boral Capital — Reiterated
Buy → Buy 2026-04-27 32% win rate (25 calls)
Needham — Reiterated
Buy → Buy 2026-03-05 20% win rate (5 calls)
D. Boral Capital — Reiterated
Buy → Buy 2026-02-11 32% win rate (25 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-01-23 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
14/30
Consensus clarity
15/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →